Department of Neurosurgery, Hokkaido University Graduate School of Medicine, North 15 West 7, Kita-ku, Sapporo, 060-8638, Japan.
Transl Stroke Res. 2011 Sep;2(3):307-15. doi: 10.1007/s12975-011-0088-y. Epub 2011 Jun 11.
The donor cell culture in animal serum-free medium is quite important for the clinical application of cell transplantation therapy. This study was aimed to test the hypothesis that the human bone marrow stromal cells (hBMSC) expanded with fetal calf serum (FCS)-free, platelet lysate (PL)-containing medium retain their biological features favoring central nervous system regeneration. The hBMSC were cultured with 5% PL or 10% FCS. Their phenotypes were analyzed with flow cytometry, and their production of growth factors was quantified with enzyme-linked immunosorbent assay. Their capacity of neural differentiation was verified by immunocytochemistry. There was no significant difference in morphology and cell surface marker between the hBMSC-FCS and hBMSC-PL. Both of them were positive for CD44, CD90, CD105, and CD166 and were negative for CD34, CD45, and CD271. The production of human brain-derived neurotrophic factor, human hepatocyte growth factor, human β-nerve growth factor, and human platelet-derived growth factor-BB did not differ between the two groups, although the hBMSC-PL produced significantly more amount of TGF-β1 than the hBMSC-FCS. There was no significant difference in their in vitro differentiation into the neurons and astrocytes between the two groups. The hBMSC expanded with PL-containing medium retain their biological capacity of neural differentiation and neuroprotection. The PL may be a clinically valuable and safe substitute for FCS in expanding the hBMSC for cell therapy.
无血清培养基中的供体细胞培养对于细胞移植治疗的临床应用非常重要。本研究旨在验证以下假设:用人胎牛血清(FCS)-无、血小板裂解物(PL)培养基扩增的人骨髓基质细胞(hBMSC)保留有利于中枢神经系统再生的生物学特征。将 hBMSC 分别用 5% PL 或 10% FCS 培养。通过流式细胞术分析其表型,通过酶联免疫吸附试验定量检测其生长因子的产生。通过免疫细胞化学验证其神经分化能力。hBMSC-FCS 和 hBMSC-PL 在形态和细胞表面标志物方面没有显著差异。它们均为 CD44、CD90、CD105 和 CD166 阳性,CD34、CD45 和 CD271 阴性。两组间人源性脑源性神经营养因子、人肝细胞生长因子、人β-神经生长因子和人血小板衍生生长因子-BB 的产生没有差异,尽管 hBMSC-PL 产生的 TGF-β1 明显多于 hBMSC-FCS。两组间体外向神经元和星形胶质细胞分化的能力没有差异。含 PL 的培养基中扩增的 hBMSC 保留了其神经分化和神经保护的生物学能力。PL 可能是临床上有价值且安全的 FCS 替代品,可用于细胞治疗中扩增 hBMSC。